Clinical Trial Recruitment
Patient recruitment measured past the lead.
Clinical-trial acquisition only works when media, qualification, site operations, and downstream enrollment economics are treated as one system. We connect acquisition decisions to what happens after the form fill.
How we think about it
The recruitment funnel is the product.
A cheap lead is not useful if the patient is outside geography, fails obvious eligibility criteria, cannot reach a site, never completes screening, or enters a workflow the site cannot absorb. We design acquisition around the constraints that determine whether interest can become an enrolled participant.
Qualification before volume
Pre-screening and exclusion logic should remove obvious mismatches early enough to protect coordinator capacity without turning the advertising funnel into a clinical decision system.
Downstream measurement
Screening and enrollment outcomes are reconciled back to acquisition source so creative, targeting, bidding strategy, and budget allocation can be judged on more than platform-visible leads.
Operational reality
Geography, site capacity, recruitment timelines, protocol complexity, and follow-up speed all affect what a viable acquisition program can support.
Capabilities
Where the capabilities connect
Privacy & measurement
Patient data stays where it belongs.
Patient-level health information stays in the approved intake, CTMS, or clinical system. Downstream outcomes can be reconciled to source for reporting and media decisions, while any platform-side conversion signal is limited to what the platform's terms and the applicable privacy framework permit.
Next step
Planning a recruitment program?
Share the protocol, geography, site model, and enrollment target. We'll tell you where we think acquisition is likely to work — and where it is likely to break.